EMMERITA MORRIS: Open Payments
NPI 1629306030 · WESTMINSTER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 42 payments from 12 companies in 2025. Trend: 2023 $822 · 2024 $899 · 2025 $983
Food & beverage: $884Education: $99
| Company | Payments | Amount |
|---|---|---|
| Sage Therapeutics, LLC | 13 | $319 |
| Astellas Pharma US Inc | 7 | $228 |
| Exeltis, USA Inc. | 4 | $76 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| CooperSurgical, Inc. | 2 | $43 |
| PFIZER INC. | 2 | $42 |
| Organon LLC | 2 | $41 |
| MILLICENT US INC | 2 | $29 |
Products named: ZURZUVAE, Veozah, SLYND, Qelbree, Paragard T 380A, NEXPLANON, Mirena, INTRAROSA.
Industry payments across MD — which companies pay providers there.
